COVID-19 vaccine from Novavax: application for indication extension to 12 to 18-year-olds and booster dose submitted
Bern, 7.7.2022 - Future Health Pharma GmbH represents Novavax in Switzerland and is considered to be the marketing authorisation holder for the Nuvaxovid vaccine. The company submitted an application for an indication extension for the vaccine to adolescents aged 12 to 18 years. It also applied for authorisation of a new dosage recommendation for a booster dose for persons aged 18 years and over.